Physician profile
Mark E Higgins
NPI 1134193469
$75,325.18
in general payments reported to CMS, 2019-2025
64 companies · $4,181 in 2025
The $4,181 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,085 · 2021: $11K · 2022: $13K · 2023: $4,495 · 2024: $6,034 · 2025: $4,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,709.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41,522.00 | 2019-2025 | Biktarvy, Yeztugo |
| Viiv Healthcare Company | $13,122.61 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Abbvie INC. | $2,408.16 | 2019-2025 | |
| Emd Serono, INC. | $2,213.43 | 2019-2025 | Serostim |
| Novo Nordisk INC | $1,441.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,410.32 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $1,356.77 | 2019-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Lilly USA, LLC | $1,020.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $899.52 | 2019-2025 | |
| Janssen Biotech, INC. | $778.07 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $758.90 | 2019-2025 | Egrifta, Trogarzo, Egrifta Sv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $572.54 | 2019-2024 | Xifaxan |
| Napo Pharmaceuticals INC | $555.68 | 2019-2025 | Mytesi |
| Bausch Health US, LLC | $547.10 | 2019-2024 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $461.40 | 2020-2025 | Belbuca, Xtampza |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.